Urge Roche to lower the cost of its breast cancer drug Kadcyla.

av: Donna boden
mottagare: Roche

Kadcyla has been approved in the E.U. for advanced HER2-positive breast cancer extending patients lives by a median of six months in clinical studies.

Roche's website states that: "Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients" however at £90,000 cost per patient NICE have been unable to approve it for NHS use.

Please sign this petition, urging Roche to lower their price so that they can achieve their own heathcare strategy aims and allow the people this drug has been made for to be able to benefit from it.

Signera petitionen

Se fler petitioner:

Hälsosam

Du har JavaScript inaktiverat. Utan den skulle vår webbplats inte fungera korrekt.

sekretesspolicy

genom att skriva under accepterar du användarvillkor för Care2
Du kan hantera dina epostabonnemang när som helst.

Har problem med att skriva under detta? Låt oss veta.

Care2

Urge Roche to lower the cost of its breast cancer drug Kadcyla.